References
- Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis. In: Swerdlow S, Campo E, Harris NL, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. Pp 53–63.
- Pardanani A. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:401–411.
- Wang SA, Hutchinson L, Tang G, et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol 2013; 88:219–224.
- Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010;69:1838–1841.
- Oranje AP, Mulder PG, Heide R, et al. Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis. Clin Exp Dermatol 2002;27:502–506.
- Horny HP, Kaiserling E, Parwaresch MR, et al. Lymph node findings in generalized mastocytosis. Histopathology 1992;21: 439–446.
- Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991;96:2S–4S; discussion 4S, 60S–65S.
- Povoa P, Ducla-Soares J, Fernandes A, et al. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med 1991; 229:475–477.
- Kinkor Z, Sima R, Skalova A, et al. [Isolated lymphadenopathy as the first presentation of systemic mastocytosis–description of two cases]. Cesk Patol 2006;42:34–38.
- Liu AY, Lowe RC, Levy BD, et al. Clinical problem-solving. A rash hypothesis. N Engl J Med 2010;363:72–78.
- Hauswirth AW, Sperr WR, Ghannadan M, et al. A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk Res 2002;26:601–606.
- Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009;84:790–794.
- Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093–3096.
- Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010;85:921–925.
- Gotlib J, Kluin-Nelemans HC, George TI, et al. KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood 2012;120(Suppl. 1): Abstract 799.